‘EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins

Epidermal Growth Factor Receptor (EGFR) exon 20 insertion (ex20ins) mutations occur in ∼2-3% of all non-small cell lung cancer (NSCLC) cases, representing ∼10-12% of all cancers with documented EGFR mutation [1–4]. These mutations are the third most common EGFR mutation subtype after the common sensitizing EGFR mutations, i.e. the exon 19 deletions and exon 21 L858R mutation [4] .

Source: Cancer Treatment Reviews - September 13, 2020 Category: Cancer & Oncology Authors: Jordi Remon, Lizza E.L. Hendriks, Andres F. Cardona, Benjamin Besse Tags: Anti-tumour Treatment Source Type: research